Skip to content

Royalty Pharma RPRX Market capitalization

Market capitalization at other companies

Roivant Sciences logo
Roivant SciencesROIV
$19.82B+175%
ALN
Alnylam PharmaceuticalsALNY
$43.88B+25.6%
Viatris logo
ViatrisVTRS
$15.56B+49.6%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$13.22B+19.9%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$123.83B-0.2%
Amgen logo
AmgenAMGN
$189.67B+13.3%

Other financials

Income statement

See full
Revenue$630.6M+11.0%
Operating income$563.0M+5.4%
Net income$294.7M+23.1%
EPS (diluted)$0.67+21.8%

Balance sheet

See full
Cash & equivalents$586.4M-46.1%
Total debt$9.0B+17.8%
Total equity$9.9B+1.6%
Total assets$19.8B+12.5%

Cash flow

See full
Operating cash flow$718.2M+20.5%

Valuation

See full
Enterprise value$32.19B+44.6%
P/E28.8×+14.5×
P/S9.8×+2.9×

Profitability

See full
Operating margin65.1%-18.9pp
Net margin33.9%-14.4pp

Returns & leverage

See full
Return on equity8.4%-2.7pp
Debt / equity0.9×+0.1×
Current ratio2.7×+1.1×

Where this comes from

Computed from the period-end share price: $20.55B.

The official record: Royalty Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Royalty Pharma's market capitalization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Royalty Pharma's market capitalization?
Royalty Pharma (RPRX) reported market capitalization of $20.55B in Q1 2026.
How has Royalty Pharma's market capitalization changed year-over-year?
Royalty Pharma's market capitalization increased by 52.4% year-over-year, from $13.49B to $20.55B.
What is the long-term trend for Royalty Pharma's market capitalization?
Over 4 years (2021 to 2025), Royalty Pharma's market capitalization has grown at a -3.2% compound annual growth rate (CAGR), from $68.98B to $60.48B.
What does market capitalization mean?
What the stock market says the company's equity is worth.
How do you interpret market capitalization?
A size and market-sentiment gauge, not a quality measure — interpret through valuation ratios (P/E, P/S) that relate it to fundamentals.
How does market capitalization compare across companies?
Comparable across companies as a size class; the input to every equity-price valuation multiple.